Granules India share price
NSE: GRANULESBSE: 532482Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹840.45.
29 Oct: open ₹840.00, high ₹842.85, low ₹820.00
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹22,841 Cr403rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.49
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.21%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,08,57563.3% delivered
About Granules India
Granules India Limited is a pharmaceutical company with four lines of business: active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs) and peptide contract development and manufacturing (CDMO). It runs an integrated business model across APIs, PFIs and finished dosages, and sells to pharmaceutical customers in regulated and emerging markets.
Its core products include paracetamol, metformin, ibuprofen and controlled substances. Finished dosages are the largest division of the business and cover both prescription and over-the-counter products. The peptide CDMO operations emerged as a distinct business vertical during the year to March 2026. North America is the largest market, and Europe is the market that grew fastest in that year.
The manufacturing network spans India, the USA and Switzerland. In India, plants are located in Telangana and Andhra Pradesh, including Jeedimetla, Bonthapally and Gagillapur in Telangana and Vizag in Andhra Pradesh. A further site is in Virginia in the USA, and the Granules Life Sciences facility is also in Telangana. The peptide CDMO site is at Dielsdorf in Switzerland, and a peptide platform in India works from a Centre of Excellence at IIT Hyderabad. The registered office is in Hyderabad, Telangana.
The company was incorporated in 1991. In the year to March 2026 it completed the acquisition of Senn Chemicals AG in Switzerland, which marked its entry into peptide CDMO.
Written from the annual report for the year to Mar 2026, filed 15 Jul 2026.
Sources for 21 statements, each with its page
- The portfolio spans APIs, PFIs, finished dosages and peptide CDMO products. Annual report, page 5
- The company runs an integrated business model across APIs, PFIs and finished dosages. Annual report, page 12
- Core products include paracetamol, metformin, ibuprofen and controlled substances. Annual report, page 13
- Finished dosages are the largest division. Annual report, page 13
- Peptide CDMO operations emerged as a distinct business vertical during the year. Annual report, page 13
- North America is the largest market. Annual report, page 15
- Europe is a growth market in the year. Annual report, page 15
- The manufacturing network spans India, the USA and Switzerland. Annual report, page 10
- A plant is at Jeedimetla in Telangana. Annual report, page 10
- A plant is at Vizag in Andhra Pradesh. Annual report, page 10
- Peptide CDMO site at Dielsdorf, Switzerland. Annual report, page 10
- Peptide platform in India has a Centre of Excellence at IIT Hyderabad. Annual report, page 7
- Registered office is in Hyderabad, Telangana. Annual report, page 1
- It was incorporated in 1991 (year in the CIN). Annual report, page 1
- The acquisition of Senn Chemicals AG in Switzerland was completed during the year. Annual report, page 7
- The Senn acquisition marked entry into peptide CDMO. Annual report, page 7
- A plant is at Bonthapally in Telangana. Annual report, page 10
- A site is at Gagillapur in Telangana. Annual report, page 10
- A site is in Virginia, USA. Annual report, page 10
- Granules Life Sciences facility is in Telangana. Annual report, page 10
- Finished dosages cover prescription and over-the-counter products. Annual report, page 13
Results
Consolidated; ₹ crore.Granules India quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +24.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +38.1%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,477 Crup 0.42%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹180 Crdown 10.72%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.2%
Revenue by quarter
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 967 | 1,138 | 1,197 | 1,210 | 1,297 | 1,388 | 1,471 | 1,477 |
| Net profit | 97 | 118 | 152 | 113 | 131 | 150 | 202 | 180 |
| Net margin | 10.1% | 10.3% | 12.7% | 9.3% | 10.1% | 10.8% | 13.7% | 12.2% |
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5,366 Crup 19.73%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹595 Crup 18.64%
- Net margin
- 11.1%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,435 | 1,692what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹7.23 crore, a tax on the goods the company makes that it collects and pays to the government. | 2,279 | 2,599 | 3,238 | 3,765 | 4,512 | 4,506 | 4,482 | 5,366 |
| Net profit | 165 | 133 | 236 | 335 | 549 | 413 | 517 | 405 | 502 | 595 |
| Net margin | 11.5% | 7.8% | 10.4% | 12.9% | 17.0% | 11.0% | 11.4% | 9.0% | 11.2% | 11.1% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned.Granules India PE ratio and valuation
At or below today's level on 99% of 2,452 trading days over the last 10 years.
At or below today's level on 4% of 2,467 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +27.8% | +18.3% | +7.9% | 0.3% |
| 3 years | +29.1% | +5.1% | +22.4% | 0.3% |
| 5 years | +15.8% | +2.1% | +13.0% | 0.4% |
Mutual fund holdings
89 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 61 of the 72 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 89 funds holding Granules India
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 43
- CutCut. Funds that held fewer shares than at the end of the month before.
- 29
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 16
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 Old Bridge Focused FundOld Bridge Mutual Fund | 16,50,500 | 3.08% | ₹139.7 Cr |
 Aditya Birla Sun Life Multi-Cap FundAditya Birla Sun Life Mutual Fund | 16,04,464 | 1.87% | ₹135.8 Cr |
| Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 14,13,691 | 1.96% | ₹119.7 Cr |
| Aditya Birla Sun Life Value FundAditya Birla Sun Life Mutual Fund | 14,03,100 | 1.78% | ₹118.8 Cr |
 Sundaram Aggressive Hybrid FundSundaram Mutual Fund | 12,41,794 | 1.20% | ₹105.1 Cr |
 TRUSTMF Small Cap FundTrust Mutual Fund | 6,58,330 | 1.44% | ₹55.7 Cr |
| Sundaram Small Cap FundSundaram Mutual Fund | 5,00,000 | 1.03% | ₹42.3 Cr |
| Sundaram Multi Asset Allocation FundSundaram Mutual Fund | 4,26,926 | 1.13% | ₹36.1 Cr |
 Nippon India Nifty Smallcap 250 Index FundNippon India Mutual Fund | 2,28,057 | 0.56% | ₹19.3 Cr |
| Sundaram Dynamic Asset Allocation FundSundaram Mutual Fund | 2,01,094 | 1.07% | ₹17.0 Cr |
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Granules India insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 8 off-market moves
- Others: no market trade · 6 pledge filings of unclear kind
Granules India competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Granules India in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 WockhardtWOCKPHARMA | 31,246 | 76.40 | 6.33 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Piramal PharmaPPLPHARMA | 30,725 | – | 3.77 | +9.4% | – | −2.6% | 2.3% | 0.00% |
 Rubicon ResearchRUBICON | 25,811 | 89.56 | 20.03 | – | – | 22.4% | 25.8% | 0.10% |
 Neuland LaboratoriesNEULANDLAB | 24,736 | 49.69 | 13.20 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Cohance LifesciencesCOHANCE | 18,416 | 173.36 | 4.71 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Shilpa MedicareSHILPAMED | 18,299 | 61.55 | 7.06 | +27.9% | +167.6% | 12.0% | 10.9% | 0.06% |
 Caplin Point LaboratoriesCAPLIPOINT | 18,061 | 27.15 | 5.04 | +15.0% | +17.7% | 20.7% | 19.8% | 0.34% |
 Onesource Specialty PharmaONESOURCE | 17,999 | – | 3.04 | +10.7% | −103.9% | 0.0% | 1.5% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Granules India dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossary| Ex-date | Type | Per share |
|---|---|---|
| 30 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.75 |
| 31 Jul 2025 | Final | ₹1.50 |
| 30 Jul 2024 | Final | ₹1.50 |
| 3 Aug 2023 | Final | ₹1.50 |
| 19 Jul 2022 | Final | ₹0.75 |
| 17 Feb 2022 | Interim | ₹0.25 |
Latest announcements
Routine notices left out.Granules India announcements
Oct 2026
26 Oct · Analysts
23 Oct
23 Oct · Board meeting
7 Oct · Business
2 Oct
Sep 2026
26 Sep · Analysts
Granules India share price by year
Each calendar year to 2025.Granules India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 598.50 | +1.0% | 617.35 | 431.10 |
| 2024 | 592.30 | +46.1% | 718.10 | 392.10 |
| 2023 | 405.45 | +27.2% | 405.45 | 270.95 |
| 2022 | 318.80 | −5.2% | 378.65 | 233.35 |
| 2021 | 336.20 | −4.5% | 386.85 | 294.15 |
| 2020 | 352.15 | +186.1% | 428.00 | 116.85 |
| 2019 | 123.10 | +37.2% | 131.30 | 84.80 |
| 2018 | 89.75 | −34.7% | 146.75 | 72.80 |
| 2017 | 137.45 | +27.2% | 152.05 | 101.20 |
| 2016 | 108.05 | −27.4% | 150.50 | 99.10 |
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 824.00 | 844.55 | 824.00 | 840.45 | 836.23 | 2,29,754 | 49.0% |
| 27 Oct 2026 | 820.05 | 853.50 | 817.00 | 830.55 | 836.30 | 7,83,735 | 54.9% |
| 26 Oct 2026 | 792.90 | 825.95 | 792.25 | 820.55 | 817.86 | 6,93,186 | 44.4% |
| 23 Oct 2026 | 813.00 | 822.00 | 791.00 | 794.75 | 803.81 | 8,83,843 | 52.9% |
| 22 Oct 2026 | 807.00 | 820.25 | 796.05 | 817.00 | 811.11 | 5,12,091 | 56.8% |
| 21 Oct 2026 | 803.00 | 814.45 | 794.15 | 807.65 | 805.98 | 6,57,725 | 54.8% |
| 19 Oct 2026 | 818.90 | 836.95 | 799.30 | 806.05 | 820.84 | 8,74,275 | 37.7% |
| 16 Oct 2026 | 815.00 | 833.50 | 801.90 | 825.35 | 822.12 | 7,72,564 | 48.5% |
| 15 Oct 2026 | 814.80 | 827.50 | 803.25 | 811.95 | 817.45 | 7,84,945 | 43.0% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 23 Mar 2015 | Split | 0.1000 | Each share became 10. |
Company details
- NSE symbol
- GRANULES
- BSE code
- 532482
- ISIN
- INE101D01020
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.granulesindia.com
- CIN
- L24110TG1991PLC012471
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1991
- Registered office
- 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad 500084, Telangana
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments